Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray
- 11 June 2004
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 17 (10), 1217-1222
- https://doi.org/10.1038/modpathol.3800169
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple MyelomaAmerican Journal of Clinical Pathology, 2004
- Blimp-1 Is Required for the Formation of Immunoglobulin Secreting Plasma Cells and Pre-Plasma Memory B CellsImmunity, 2003
- CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myelomaBlood, 2003
- Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myelomaBlood, 2002
- Roles of EBF and Pax-5 in B lineage commitment and developmentSeminars in Immunology, 2002
- The Value of Anti-Pax-5 Immunostaining in Routinely Fixed and Paraffin-Embedded SectionsThe American Journal of Surgical Pathology, 2002
- Blimp-1-Dependent Repression of Pax-5 Is Required for Differentiation of B Cells to Immunoglobulin M-Secreting Plasma CellsMolecular and Cellular Biology, 2002
- High‐sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myelomaBritish Journal of Haematology, 1999
- Molecular mechanisms regulating CD19, CD20 and CD22 gene expressionImmunology Today, 1994
- Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and stagingBritish Journal of Haematology, 1982